ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

19 links0 made here, not in the record49 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule basedReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT03498521A Phase II Randomized StudyComparing the Efficacy andSafety of Targeted Therapyor Cancer ImmunotherapyVersus Platinum-BasedChemotherapy in PatientsWith Cancer of UnknownHoffmann-La RochePhase 2 · completedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSNeoplasms, Unknown PrimaryThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionDRUGSAlectinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionHhAntag691Entry “Vismodegib”, read by our name …›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundIpatasertibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · TestedBackground · optionOlaparibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 3 · Claude Opus 5.5 · BackgroundNov 3 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTestedErlotinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundBevacizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundVemurafenibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCobimetinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionTrastuzumabEntry “Trastuzumab Subcutaneous (SC)”…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPertuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 3 · Claude Opus 5.5 · BackgroundNov 3 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTestedAtezolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTestedCarboplatinIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorPaclitaxelIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCisplatinIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorGemcitabineIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorEntrectinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · TestedBackground · optionIvosidenibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPemigatinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Alectinib

From the registry record3 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Alectinib”the record gives no role
→judged=agrees=agrees
How the 3 judgments split100%of judgments with a known value say Background · option
Background · 3

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2AlectinibClaude Opus 5.5BackgroundReplaced
Nov 2HhAntag691Claude Opus 5.5BackgroundCurrent
Nov 2IpatasertibClaude Opus 5.5TestedReplaced
Nov 2OlaparibClaude Opus 5.5BackgroundReplaced
Nov 2ErlotinibClaude Opus 5.5BackgroundCurrent
Nov 2BevacizumabClaude Opus 5.5BackgroundCurrent
Nov 2VemurafenibClaude Opus 5.5BackgroundCurrent
Nov 2CobimetinibClaude Opus 5.5BackgroundReplaced
Nov 2TrastuzumabClaude Opus 5.5BackgroundCurrent
Nov 2PertuzumabClaude Opus 5.5BackgroundReplaced
Nov 2AtezolizumabClaude Opus 5.5BackgroundReplaced
Nov 2CarboplatinClaude Opus 5.5ComparatorCurrent
Nov 2PaclitaxelClaude Opus 5.5BackgroundCurrent
Nov 2CisplatinClaude Opus 5.5ComparatorCurrent
Nov 2GemcitabineClaude Opus 5.5ComparatorCurrent
Nov 2EntrectinibClaude Opus 5.5TestedReplaced
Nov 2IvosidenibClaude Opus 5.5TestedCurrent
Nov 2PemigatinibClaude Opus 5.5TestedCurrent
Nov 3OlaparibClaude Opus 5.5BackgroundReplaced
Nov 3PertuzumabClaude Opus 5.5BackgroundReplaced
Nov 3OlaparibClaude Opus 5.5TestedReplaced
Nov 3AtezolizumabClaude Opus 5.5TestedCurrent
Nov 3PertuzumabClaude Opus 5.5TestedReplaced
Nov 10IpatasertibClaude Opus 5.5Background · optionCurrent
Nov 10OlaparibClaude Opus 5.5TestedCurrent
Nov 10PertuzumabClaude Opus 5.5TestedCurrent
Nov 10AlectinibClaude Opus 5.5Background · optionCurrent
Nov 10CobimetinibClaude Opus 5.5Background · optionCurrent
Nov 10EntrectinibClaude Opus 5.5Background · optionCurrent
Nov 14Neoplasms, Unknown PrimaryRule based · condition-kind ruleFinest filed termCurrent
Nov 18AlectinibRule based · role ruleBackgroundAgrees
Nov 18HhAntag691Rule based · role ruleBackgroundAgrees
Nov 18IpatasertibRule based · role ruleTestedOverridden
Nov 18OlaparibRule based · role ruleBackgroundOverridden
Nov 18ErlotinibRule based · role ruleBackgroundAgrees
Nov 18BevacizumabRule based · role ruleBackgroundAgrees
Nov 18VemurafenibRule based · role ruleBackgroundAgrees
Nov 18CobimetinibRule based · role ruleBackgroundAgrees
Nov 18TrastuzumabRule based · role ruleBackgroundAgrees
Nov 18PertuzumabRule based · role ruleBackgroundOverridden
Nov 18AtezolizumabRule based · role ruleBackgroundOverridden
Nov 18CarboplatinRule based · role ruleComparatorAgrees
Nov 18PaclitaxelRule based · role ruleBackgroundAgrees
Nov 18CisplatinRule based · role ruleComparatorAgrees
Nov 18GemcitabineRule based · role ruleComparatorAgrees
Nov 18EntrectinibRule based · role ruleTestedOverridden
Nov 18IvosidenibRule based · role ruleTestedAgrees
Nov 18PemigatinibRule based · role ruleTestedAgrees
As of nowNeoplasms, Unknown PrimaryRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.